BrainsWay Ltd. ADR (BWAY)
NASDAQ: BWAYHealthcareMedical DevicesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
BWAY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $467.74M
- P/E (TTM)
- 50.52
- Forward P/E
- 22.93
- EPS (TTM)
- $0.23
- Dividend yield
- None
- 52-week range
- 7.14 – 17.40
- Day range
- 11.45 – 11.76
- Volume / Avg
- 132.35K / 119.50K
- Beta
- —
- Shares outstanding
- 40.25M
52-week range
BWAY stock today
Shares of BrainsWay (BWAY) finished lower on Oct 7 at $11.62, a drop of 2.27% or $0.27 per share, versus the S&P 500's 0.22% decline. Shares are 33.2% below their 52-week high of $17.40, set on Aug 12, 2026 and 62.9% above the 52-week low of $7.14, in the middle of the past year's range. BWAY is up 22.2% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 52.6%.
BrainsWay trades at 50.5x its trailing twelve-month earnings per share of $0.23. Its forward P/E of 22.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About BrainsWay
Company profileBrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
- Sector
- Healthcare
- Industry
- Medical Devices
- CEO
- Mr. Hadar Levy
- Headquarters
- Jerusalem
- Employees
- 129
- IPO year
- 2019
- Website
- brainsway.com
Analyst forecast
ForecastConsensus (3 analysts)
none
Avg. price target
$19.27+65.83%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
BrainsWay peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SENSSenseonics Holdings Inc. | 9.16 | -8.03% | $484.33M | vs BWAY |
| MASS908 Devices Inc. | 11.78 | -4.46% | $486.91M | vs BWAY |
| SGHTSight Sciences Inc. | 8.47 | -1.05% | $466.60M | vs BWAY |
| CERSCerus Corporation | 2.29 | -2.14% | $461.49M | vs BWAY |
| TCMDTactile Systems Technology Inc. | 22.02 | -0.77% | $498.80M | vs BWAY |
| NPCENeuropace Inc. | 12.76 | +0.71% | $437.98M | vs BWAY |
| DCTHDelcath Systems Inc. | 15.38 | -0.19% | $533.67M | vs BWAY |
| SSIISS Innovations International Inc. | 2.74 | -0.72% | $548.00M | vs BWAY |
Indexes, lists and sector
Appears in lists
BrainsWay stock FAQ
What is BrainsWay's stock price today?
BWAY last traded at $11.62 as of Oct 7, 4:00 PM EDT, down 2.27% on the day. Prices are delayed at least 15 minutes.
Does BrainsWay pay a dividend?
No. BrainsWay does not currently pay a regular cash dividend.
What is BWAY's P/E ratio?
BWAY trades at a trailing P/E ratio of 50.52 and a forward P/E of 22.93.
Who is BrainsWay's CEO?
Mr. Hadar Levy is the chief executive officer of BrainsWay Ltd. ADR, which has about 129 employees.
Has BWAY ever split its stock?
Yes. The most recent BWAY stock split was a 2-for-1 split on Mar 4, 2026.
What is the BWAY 52-week high?
The 52-week high for BWAY is $17.40 and the 52-week low is $7.14. The stock is currently 33.2% below its high.